Shopping Cart
Remove All
Your shopping cart is currently empty
Amivantamab (FUT8-KO) is a humanized dual-specificity antibody targeting EGFR-MET, with FUT8 knocked out, exhibiting immunotherapeutic anticancer activity. This compound inhibits ligand binding, enhances the internalization and degradation of receptor-antibody complexes, and stimulates macrophage-mediated phagocytosis and natural killer cell cytotoxicity, both of which are Fc-dependent.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | Inquiry | Backorder | Backorder | |
| 5 mg | Inquiry | Backorder | Backorder |
| Description | Amivantamab (FUT8-KO) is a humanized dual-specificity antibody targeting EGFR-MET, with FUT8 knocked out, exhibiting immunotherapeutic anticancer activity. This compound inhibits ligand binding, enhances the internalization and degradation of receptor-antibody complexes, and stimulates macrophage-mediated phagocytosis and natural killer cell cytotoxicity, both of which are Fc-dependent. |
| Storage | -20°C for 1 year | Shipping with blue ice. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.